MPI-676 is Medtrina’s endometriosis product candidate, developed subject to an exclusive global licensing agreement with AstraZeneca and based on anastrozole, a third generation aromatase inhibitor (AI). MPI-676 is ready for evaluation in a Phase IIb dose ranging trial.
Femathina™ (MPI-674) is Meditrina’s second product candidate. MPI-674 is an AI with a well-established, multi-year, chronic safety profile that Meditrina is repurposing for endometrial thinning prior to endometrial ablation to treat abnormal uterine bleeding (AUB). MPI-674 has been evaluated in a Phase IIa clinical trial.
Currently approved for the chronic treatment of estrogen-dependent tumors in postmenopausal women, AIs are being investigated for efficacy in a variety of additional women’s health conditions. Currently marketed AIs are third generation products, the culmination of more than two decades of drug development efforts. Meditrina holds the exclusive worldwide rights to several patent applications covering the use of AIs in gynecologic indications.